Ethiodized oil

Identification

Name
Ethiodized oil
Accession Number
DB00965  (APRD00960)
Type
Small Molecule
Groups
Approved
Description

Ethiodized oil is used by injection as a radio-opaque contrast agent. It is composed of iodine combined with ethyl esters of fatty acids of poppyseed oil, primarily as ethyl monoiodostearate and ethyl diiodostearate. The precise structure is not known.

Synonyms
  • EOE 13
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LipiodolInjection480 mg/mLIntra-arterial; Intralymphatic; IntrauterineGuerbet2014-03-21Not applicableUs
Lipiodol Ultra FluidLiquid380 mgIntracavitary; ParenteralGuerbet1977-12-31Not applicableCanada
International/Other Brands
Ethiodol
Categories
UNII
KZW0R0686Q
CAS number
8008-53-5
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

For use as a radio-opaque medium for hysterosalpingography and lymphography, and as an antineoplastic agent when part of the iodine is 131-I. It is also used in follow-up imaging for chemoembolization.

Structured Indications
Pharmacodynamics

There has been little detailed investigation of the metabolic fate of ethiodized oil in either man or animals. However, the fate of ethiodized oil following Iymphangiography in dogs has been reported. Koehler et al. employed I131-tagged ethiodol for lymphangiography in dogs and analyses of individual organs at various time intervals were done. The investigators reported an average of only 25% of the injected medium was retained in the lymphatics at the end of three days. An average of 50% was recovered from the lungs. They found the remainder of injected activity was fairly uniformly distributed throughout the body. Urinary excretion in the form of inorganic iodine was revealed as the chief mode of iodine loss from the system.

Mechanism of action

Ethiodized oil is selectively retained in tumor vessels for long periods, and is used for imaging organs such as liver, lung, stomach, and thyroid. Labeled with I-131 or other beta emitters (Y-90 or P-32), ethiodized oil can deliver a high internal radiation dose to certain tumors with minimal effect on healthy tissues.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Urinary excretion in the form of inorganic iodine was revealed as the chief mode of iodine loss from the system.

Half life
Not Available
Clearance
Not Available
Toxicity

Intravenous LD50 in dog is 1580mg/kg. Symptoms of overdose include dyspnea and change in clotting factors.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ethiodized oil.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Ethiodized oil.Experimental
AldesleukinThe risk of a hypersensitivity reaction to Ethiodized oil is increased when it is combined with Aldesleukin.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Ethiodized oil.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ethiodized oil.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ethiodized oil.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Ethiodized oil.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ethiodized oil.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ethiodized oil.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Ethiodized oil.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ethiodized oil.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ethiodized oil.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Ethiodized oil.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Ethiodized oil.Experimental
MetforminThe risk or severity of adverse effects can be increased when Ethiodized oil is combined with Metformin.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Ethiodized oil.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Ethiodized oil.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Ethiodized oil.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethiodized oil.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Ethiodized oil.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Ethiodized oil.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ethiodized oil.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Nelson RC: Techniques for computed tomography of the liver. Radiol Clin North Am. 1991 Nov;29(6):1199-212. [PubMed:1947041]
  2. Hamm B, Wolf KJ: Contrast material for computed tomography and magnetic resonance imaging of the gastrointestinal tract. Curr Opin Radiol. 1991 Jun;3(3):474-82. [PubMed:1859783]
  3. Link [Link]
External Links
KEGG Drug
D04082
PubChem Substance
46505147
ChEMBL
CHEMBL1201458
PharmGKB
PA164768833
RxList
RxList Drug Page
Wikipedia
Ethiodized_oil
AHFS Codes
  • 36:68.00 — Roentgenography
MSDS
Download (12.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentAdvanced Hepatocellular Carcinoma / Recurrence Hepatocellular Carcinoma1
2CompletedPreventionHepatocellular,Carcinoma1
2Unknown StatusNot AvailableLiver Cancer1
2, 3Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
2, 3Unknown StatusTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentLiver Cancer1
3RecruitingDiagnosticPulmonary Lesion With Ground-glass-opacity1
3RecruitingTreatmentChild-Pugh Class A / Child-Pugh Class B / Recurrent Hepatocellular Carcinoma1
3RecruitingTreatmentHepatocellular,Carcinoma3
3RecruitingTreatmentHepatocellular,Carcinoma / Portal Vein Tumor Thrombus1
3TerminatedPreventionHepatocellular,Carcinoma / Liver Cirrhosis / Neoplasm Recurrence, Local / Neoplasms, Hepatic / Recurrences1
4Not Yet RecruitingTreatmentHepatocellular,Carcinoma / Neoplastic Cells, Circulating1
4RecruitingTreatmentMetastatic Colorectal Cancers1
Not AvailableCompletedTreatmentGastric Varices / Portal Hypertension1

Pharmacoeconomics

Manufacturers
  • Guerbet llc
Packagers
Not Available
Dosage forms
FormRouteStrength
InjectionIntra-arterial; Intralymphatic; Intrauterine480 mg/mL
LiquidIntracavitary; Parenteral380 mg
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
boiling point (°C)125 °C (at 8mm Hg)Not Available
water solubilityInsolubleNot Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34